Arrowhead Pharmaceuticals Stock Income Statements

Arrowhead Pharmaceuticals Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Operating Profit

Net Income

Arrowhead Pharmaceuticals Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-06-30	2013-05-07	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2009-12-31	2009-09-30	2009-06-30	2008-12-31	2008-06-30	2008-05-07	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31

revenue	27,767,000	542,709,000			3,551,000	16,097,000	15,825,000	146,267,000	62,546,000	31,575,000	32,412,000	151,805,000	27,439,000	38,283,000	45,891,000	32,811,000	21,303,000	7,632,855	27,375,778	23,528,853	29,454,579	43,292,770	42,696,636	48,148,275	34,657,896	11,255,000	9,342,498	8,985,930	4,365,496	8,713,786	39,583	43,750	43,750	31,250	123,750	43,750	170,750	43,750	43,750	43,750	43,750	43,750	43,750	43,750	159,016	43,750		43,750	159,016	4,035,709	47,917	31,250	23,958	3,695,820			4,994,969	7,688,333	133,990	148,068								157,498.5	622,599	-3,697	11,092	39,229	246,229	57,500	252,500
yoy	681.95%	3271.49%			-94.32%	-49.02%	-51.18%	-3.65%	127.95%	-17.52%	-29.37%	362.66%	28.80%	401.56%	67.63%	39.45%	-27.68%	-82.37%	-35.88%	-51.13%	-15.01%	284.65%	357.02%	435.82%	693.91%	29.16%	23502.30%	20439.27%	9878.28%	27784.12%	-68.01%	0.00%	-74.38%	-28.57%	182.86%	0.00%	290.29%	0.00%	0.00%	0.00%	-72.49%	0.00%		0.00%	0.00%	-98.92%		40.00%	563.73%	9.20%			-99.52%	-51.93%														301.48%	152.85%	-106.43%	-95.61%
qoq	-94.88%				-77.94%	1.72%	-89.18%	133.86%	98.09%	-2.58%	-78.65%	453.25%	-28.33%	-16.58%	39.86%	54.02%	179.10%	-72.12%	16.35%	-20.12%	-31.96%	1.40%	-11.32%	38.92%	207.93%	20.47%	3.97%	105.84%	-49.90%	21913.96%	-9.52%	0.00%	40.00%	-74.75%	182.86%	-74.38%	290.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-72.49%	263.47%			-72.49%	-96.06%	8322.29%	53.33%	30.44%	-99.35%				-35.03%	5637.99%	-9.51%									-74.70%	-16940.65%	-133.33%	-71.72%	-84.07%	328.22%	-77.23%
operating expenses:
research and development	162,368,000	133,102,000	152,431,000	101,122,000	116,491,000	99,855,000	94,757,000	74,881,000	83,695,000	83,377,000	72,180,000	75,985,000	65,765,000	65,766,000	59,325,000	44,697,000	36,555,000	43,484,893	32,573,134	29,443,335	23,373,616	23,386,305	19,291,710	20,798,628	17,572,043	15,993,880	11,136,741	11,438,216	9,527,051	8,280,406	9,423,195	10,020,826	10,338,833	11,671,598	7,490,400	11,640,794	17,744,312	10,389,436	6,392,200	5,216,446	3,133,014	8,418,311	1,756,527	2,125,019	1,576,666	1,756,527		2,125,019	1,576,666	39,271,746	1,219,236	1,358,691	1,140,904	37,660,599	365,618	140,658	3,509,458	53,874,993	227,804	277,788	45,990,806	2,519,325	3,923,304	3,349,423		1,690,037	1,664,689	20,001,639	8,563,401	4,465,475		984,976.5	1,081,332	1,136,181
general and administrative	30,949,000	28,405,000	23,710,000	25,069,000	23,605,000	24,572,000	23,771,000	23,221,000	20,985,000
total operating expenses	193,317,000	161,507,000	176,141,000	126,191,000	140,096,000	124,427,000	118,528,000	98,102,000	104,680,000	115,405,000	105,321,000	110,252,000	90,760,000	103,166,000	77,759,000	61,043,000	45,357,000	57,751,947	43,321,640	45,769,108	34,308,173	33,654,721	24,100,887	26,137,583	23,711,752	22,424,109	15,056,662	15,115,572	19,267,383	18,963,999	19,381,070	21,308,605	19,385,020	21,826,365	16,117,456	29,676,493	25,286,026	25,273,582	12,743,850	11,256,248	7,053,132	22,398,058	6,433,615	5,434,038	4,969,037	6,433,615		5,434,038	4,969,037	105,540,989	6,850,853	4,900,007	4,062,997	92,905,072	1,770,165	1,811,618	6,004,286	128,867,102	2,298,099	2,308,286	107,530,443	4,956,951	9,376,404	9,971,212		7,407,638	6,960,778	46,087,190	13,672,290	8,432,841	4,484,732	8,798,971	4,729,227	4,002,650	4,305,232
operating income	-165,550,000	381,202,000	-176,141,000	-126,191,000	-136,545,000	-108,330,000	-102,703,000	48,165,000	-42,134,000	-83,830,000	-72,909,000	41,553,000	-63,321,000	-64,883,000	-31,868,000	-28,232,000	-24,054,000	-50,119,092	-15,945,862	-22,240,255	-4,853,594	9,638,049	18,595,749	22,010,692	10,946,144	-11,169,109	-5,714,164	-6,129,642	-14,901,887	-10,250,213	-19,341,487	-21,264,855	-19,341,270	-21,795,115	-15,993,706	-29,632,743	-25,115,276	-25,229,832	-12,700,100	-11,212,498	-7,009,382	-22,354,308	-6,389,865	-5,390,288	-4,810,021	-6,389,865		-5,390,288	-4,810,021	-101,505,280	-6,802,936	-4,868,757	-4,039,039	-89,209,252	-1,770,165	-1,811,618	-1,009,317	-121,178,769	-2,164,109	-2,160,218	-103,578,368	-2,323,760	-8,674,681	-9,896,582		-7,072,689	-6,885,123	-44,503,202	-13,397,292	-8,436,538	-4,473,640	-8,759,742	-4,482,998	-3,945,150	-4,052,732
yoy	21.24%	-451.89%	71.51%	-362.00%	224.07%	29.23%	40.86%	15.91%	-33.46%	29.20%	128.78%	-247.18%	163.25%	29.46%	99.85%	26.94%	395.59%	-620.01%	-185.75%	-201.04%	-144.34%	-186.29%	-425.43%	-459.09%	-173.45%	8.96%	-70.46%	-71.17%	-22.95%	-52.97%	20.93%	-28.24%	-22.99%	-13.61%	25.93%	164.28%	258.31%	12.86%	98.75%	108.01%	45.72%	249.84%		0.00%	0.00%	-93.70%		10.71%	19.09%	13.78%	284.31%	168.75%	300.18%	-26.38%	-18.20%	-16.14%	-99.03%	5114.77%	-75.05%	-78.17%		-67.14%	25.99%	-77.76%		-16.17%	53.90%	408.04%	198.85%	113.85%	10.39%
qoq	-143.43%	-316.42%	39.58%	-7.58%	26.05%	5.48%	-313.23%	-214.31%	-49.74%	14.98%	-275.46%	-165.62%	-2.41%	103.60%	12.88%	17.37%	-52.01%	214.31%	-28.30%	358.22%	-150.36%	-48.17%	-15.51%	101.08%	-198.00%	95.46%	-6.78%	-58.87%	45.38%	-47.00%	-9.04%	9.95%	-11.26%	36.27%	-46.03%	17.99%	-0.45%	98.66%	13.27%	59.96%	-68.64%	249.84%	18.54%	12.06%	-24.72%			12.06%	-95.26%	1392.08%	39.73%	20.54%	-95.47%	4939.60%	-2.29%	79.49%	-99.17%	5499.48%	0.18%	-97.91%	4357.36%	-73.21%	-12.35%			2.72%	-84.53%	232.18%	58.80%	88.58%	-48.93%	95.40%	13.63%	-2.65%
operating margin %	-596.21%	70.24%			-3845.25%	-672.98%	-648.99%	32.93%	-67.36%	-265.49%	-224.94%	27.37%	-230.77%	-169.48%	-69.44%	-86.04%	-112.91%	-656.62%	-58.25%	-94.52%	-16.48%	22.26%	43.55%	45.71%	31.58%	-99.24%	-61.16%	-68.21%	-341.36%	-117.63%	-48863.12%	-48605.38%	-44208.62%	-69744.37%	-12924.21%	-67731.98%	-14708.80%	-57668.19%	-29028.80%	-25628.57%	-16021.44%	-51095.56%	-14605.41%	-12320.66%	-3024.87%	-14605.41%		-12320.66%	-3024.87%	-2515.18%	-14197.33%	-15580.02%	-16858.83%	-2413.79%			-20.21%	-1576.14%	-1615.13%	-1458.94%								-28256.27%	-2151.83%	228199.57%	-40332.13%	-22329.76%	-1820.66%	-6861.13%	-1605.04%
other income:
interest income	11,019,000	9,615,000	6,498,000	6,250,000	2,802,000	3,885,000	4,172,000	4,560,000	-167,000	1,583,000	1,240,000	1,054,000	1,156,000	1,148,000	1,280,000	1,524,000	2,169,000	2,271,301	2,334,649	2,404,685	2,179,866	2,240,409	1,739,959	1,886,290	1,091,109	402,745	131,358	108,744	25,148	149,878	34,103	79,060	100,380	52,251	162,366	198,113	237,417	131,262	226,424	119,390	40,578	259,101	-48,252	-27,567	7,416	-48,252		-27,567	7,416	2,723,118	14,436	5,015	7,875	2,643,663	20,531	35,037	3,338	2,811,608	-12,877	-22,025	2,996,419	-78,526	13,535	115,158		232,879	315,373	1,420,461	238,277	328,098	313,217	271,697	223,443	181,310	176,516
interest expense	-24,382,000	-21,639,000	-5,094,000	-7,244,000	-5,367,000	-5,262,000	-5,158,000	-5,057,000
other	-176,000	438,000	760,000	189,000	421,000	717,000	306,000	8,000
total other income	-13,539,000	-11,586,000	2,164,000	-805,000	-2,144,000	-660,000	-680,000	-489,000	340,000	1,673,000	863,000	2,813,000	449,000	1,511,000	1,944,000	1,414,000	3,322,000	1,688,777	2,334,649	2,404,685	2,179,866	2,240,409	1,739,959	1,886,290	1,091,109	410,238	194,423	87,085	2,815,779	-479,273	-79,256	448,995	76,856	-424,471	57,653	948,750	2,539,994	489,096	1,073,649	-2,770,202	-3,676,350	-70,924	212,237	-1,549,395	29,312	212,237		-1,549,395	29,312	7,200,278	-1,436,802	-714,875	1,352,461	6,343,376	-174,507	724,282	517,434	5,960,953	1,485,862	-70,444	5,634,752	-204,857	644,153	115,158		232,879	315,373	4,099,162	238,277	328,098	766,470	-19,781	508,850	838,564	915,779
income before income tax expense and noncontrolling interest	-179,089,000	369,616,000				-108,990,000	-103,383,000	47,676,000	-41,794,000
income tax (benefit) expense	-437,000				-3,313,000
net income including noncontrolling interest	-178,652,000	367,863,000	-173,977,000	-126,996,000	-135,376,000	-111,015,000	-104,125,000	47,676,000	-41,811,000
net income attributable to noncontrolling interest, net of tax	-3,411,000	-2,582,000	-3,184,000	-1,696,000	-2,512,000	-1,336,000	-1,179,000	-999,000	-486,000
net income attributable to arrowhead pharmaceuticals, inc.	-175,241,000	370,445,000	-170,793,000	-125,300,000	-132,864,000	-109,679,000	-102,946,000	48,675,000	-41,325,000
net income per share										-0.215	-0.68	0.42	-0.6	-0.61	-0.29	-0.26	-0.2	-0.48	-0.13	-0.2	-0.03	0.12	0.21	0.25	0.13	-0.12	-0.07	-0.08	-0.17	-0.15	-0.32	-0.35	-0.32	-0.34	-0.27	-0.51						-0.44	-0.23	-0.41		-0.23																	-0.19	-0.19		-0.15	-0.14	-0.16	-0.34	-0.18	-0.11	-0.26	-0.12	-0.1	-0.11
basic	-1.26	2.78	-1.38	-1.02	-1.24	-1.02	-0.96	0.46	-0.39
diluted	-1.26	2.75	-1.38	-1.02	-1.24	-1.02	-0.96	0.45	-0.39
weighted-average shares used for eps calculation
basic	139,039	133,363	124,199	123,285	107,415	106,750	107,004	106,757	106,039	105,426
diluted	139,039	134,484	124,199	123,285	107,415	106,750	107,004	108,143	106,039	105,426
other comprehensive income, net of tax:
unrealized gains on available-for-sale securities	876	653
foreign currency translation adjustments	91	-400	-141	-56	58	153	-79	-74	-122	4	-33	1	-39	-131	-40	-96	180	193,652	453,895	-433,564	196,074	-288,546	-31,172	-28,162	-22,180	-18,226	12,309	154,464	-192,608	51,618	-90,625	150,520	45,818	38,161	-1,982	-63,965		-70,478
comprehensive income	-177,685	368,116		-126,836				47,602		-22,655.75	-72,079	44,367	-62,911	-63,505	-29,964	-26,914	-20,552	-48,239,063	-13,157,318	-20,269,134	-2,477,654	11,416,359	20,304,536	23,868,820	12,015,073
income tax benefit		1,753,000
income before income tax benefit and noncontrolling interest			-173,977,000
other comprehensive loss, net of tax:
change in unrealized losses on available-for-sale securities			249	216	1,909
comprehensive loss			-173,869		-133,409	-113,826	-104,204		-41,933																	-10,779,497	-5,507,432	-5,888,093	-12,278,716	-10,680,268	-19,511,368	-20,665,340	-19,218,596
income before income tax (benefit) expense and noncontrolling interest				-126,996,000	-138,689,000
income tax expense						2,025,000	742,000		17,000
other income									507,000	90,000	-377,000	1,759,000	-707,000	363,000	664,000	-110,000	1,153,000											5,724	1,306,800							536,087	-53,184	-65,030	10,054	76,546	-5,331	823	259,221	-1,279,881	22,685	259,221		-1,279,881	22,685									88,963		220
operating expenses
general and administrative expenses										23,100,750	33,141,000	34,267,000	24,995,000	37,400,000	18,434,000	16,346,000	8,802,000	14,267,054	10,748,506	16,325,773	10,934,557	10,268,416	4,809,177	5,338,955	6,139,709	6,430,229	3,919,921	3,677,356	1,854,174	1,507,685	2,275,628	3,818,335	1,951,609	1,895,166	1,829,393	1,696,623	2,086,202	2,318,965	1,582,465	1,347,677	913,784	2,028,163	899,633	779,970	917,676	899,633		779,970	917,676	26,018,024	3,137,368	930,914	1,277,904	23,493,277	643,165	822,812	1,128,957	23,898,636	869,307	746,250	19,615,497	1,041,883	1,629,987	1,720,206		1,582,743	1,697,776	9,179,676	1,567,426	1,458,997		947,758.25	1,439,881	1,253,056
income before income taxes										-22,638,000	-72,046,000	44,366,000	-62,872,000	-63,372,000	-29,924,000	-26,818,000	-20,732,000	-48,430,315	-13,611,213	-19,835,570	-2,673,728	11,878,458	20,335,708	23,896,982	12,037,253	-10,758,871	-5,519,741	-6,042,557	-12,086,108	-10,729,486	-19,420,743	-20,815,860	-19,264,414	-22,219,586	-15,936,053	-28,683,993	-22,575,282	-24,740,736	-11,626,451	-13,982,700	-10,685,732
benefit from income taxes																																																									742,500
net income										-22,638,000	-72,046,000	44,366,000	-62,872,000	-63,374,000	-29,924,000	-26,818,000	-20,732,000	-48,432,715	-13,611,213	-19,835,570	-2,673,728	11,704,905	20,335,708	23,896,982	12,037,253	-10,761,271	-5,519,741	-6,042,557	-12,086,108	-10,731,886	-19,420,743	-20,815,860	-19,264,414	-22,221,986	-15,936,053	-28,683,993	-22,575,282	-24,743,136	-11,626,451	-13,982,700	-10,685,732	-22,430,532	-6,177,628	-6,940,019	-4,780,727	-6,177,628		-6,940,019	-4,780,727	-137,143,031	-8,239,061	-5,584,115	-2,686,799	-130,996,821	-2,013,414	2,699,382	-1,231,430	-122,406,813	-683,796	-1,816,429	-88,956,495	-2,528,617	-8,030,468	-7,502,162		-5,694,815	-5,233,774	-36,048,909	-12,477,548	-6,173,809	-3,707,170	-8,779,523	-3,974,148	-3,106,586	-3,136,953
yoy										-64.28%	140.76%	-265.43%	203.26%	30.85%	119.85%	35.20%	675.40%	-513.78%	-166.93%	-183.00%	-122.21%	-208.77%	-468.42%	-495.48%	-199.60%	0.27%	-71.58%	-70.97%	-37.26%	-51.71%	21.87%	-27.43%	-14.67%	-10.19%	37.07%	105.14%	111.27%	10.31%	88.20%	101.48%	123.52%	263.09%		0.00%	0.00%	-95.50%		24.28%	77.93%	4.69%	309.21%	-306.87%	118.19%	7.02%	194.45%	-248.61%	-98.62%	4740.86%	-91.48%	-75.79%		-55.60%	53.44%	-79.19%		-7.76%	41.18%	310.60%	213.97%	98.73%	18.18%
qoq										-68.58%	-262.39%	-170.57%	-0.79%	111.78%	11.58%	29.36%	-57.19%	255.83%	-31.38%	641.87%	-122.84%	-42.44%	-14.90%	98.53%	-211.86%	94.96%	-8.65%	-50.00%	12.62%	-44.74%	-6.70%	8.05%	-13.31%	39.44%	-44.44%	27.06%	-8.76%	112.82%	-16.85%	30.85%	-52.36%	263.09%	-10.99%	45.17%	-22.61%			45.17%	-96.51%	1564.55%	47.54%	107.84%	-97.95%	6406.20%	-174.59%	-319.21%	-98.99%	17801.07%	-62.35%	-97.96%	3417.99%	-68.51%	7.04%			8.81%	-85.48%	188.91%	102.10%	66.54%	-57.77%	120.92%	27.93%	-0.97%
net income margin %	0%	0%			0%	0%	0%	0%	0%	-71.70%	-222.28%	29.23%	-229.13%	-165.54%	-65.21%	-81.73%	-97.32%	-634.53%	-49.72%	-84.30%	-9.08%	27.04%	47.63%	49.63%	34.73%	-95.61%	-59.08%	-67.24%	-276.86%	-123.16%	-49063.34%	-47579.11%	-44032.95%	-71110.36%	-12877.62%	-65563.41%	-13221.25%	-56555.74%	-26574.75%	-31960.46%	-24424.53%	-51269.79%	-14120.29%	-15862.90%	-3006.44%	-14120.29%		-15862.90%	-3006.44%	-3398.24%	-17194.44%	-17869.17%	-11214.62%	-3544.46%			-24.65%	-1592.11%	-510.33%	-1226.75%								-22888.41%	-2004.11%	166995.10%	-33422.02%	-22380.19%	-1614.00%	-5402.76%	-1242.36%
net income per share										-0.215	-0.68	0.42	-0.6	-0.61	-0.29	-0.26	-0.2	-0.48	-0.13	-0.2	-0.03	0.12	0.21	0.25	0.13	-0.12	-0.07	-0.08	-0.17	-0.15	-0.32	-0.35	-0.32	-0.34	-0.27	-0.51						-0.44	-0.23	-0.41		-0.23																	-0.19	-0.19		-0.15	-0.14	-0.16	-0.34	-0.18	-0.11	-0.26	-0.12	-0.1	-0.11
weighted-average shares outstanding - basic											105,753	105,545	104,534	103,745	104,099	103,867	102,757	100,722,224	101,843,436	101,653,136	97,090,079	93,858,857	94,935,471	94,155,407	91,091,823
weighted-average shares outstanding - diluted											105,753	107,929	104,534	103,745	104,099	103,867	102,757	100,722,224	101,843,436	101,653,136	97,090,079	98,607,815	98,884,744	98,082,644	95,590,183
change in value of derivatives																											63,065	-27,383	1,483,831	-629,151	-113,359	369,935	-23,524	-534,074	-104,713	168,974	2,382,142	422,864	758,469	-2,951,225	-3,519,579	-321,324	200,747	-29,403	44,275	200,747		-29,403	44,275	3,055,065	915,387	-622,145	-66,904	1,651,356	373,734	404,152
weighted-average shares outstanding - basic and diluted																										83,638,469	74,772,103	74,629,855	71,444,600	73,898,598	59,966,955	59,779,128	59,548,672	61,050,880	59,492,867	55,719,923	54,692,392	57,358,442	51,931,989	44,321,847	37,741,743	46,933,030	26,134,183	16,461,693	14,113,620			16,461,693
salaries and payroll-related costs																													4,276,105	6,011,689	4,113,262	4,248,693	3,919,886	7,179,815	3,570,531	3,541,652	3,150,617	6,291,209	2,454,449	3,097,902	2,081,791	5,195,213	1,651,729	1,725,176	1,629,423	1,651,729		1,725,176	1,629,423	21,399,459	1,654,915
stock-based compensation																													2,424,442	2,009,694	2,750,785	2,416,839	2,380,343	4,047,849	2,486,074	2,205,079	2,014,856	3,526,888	2,038,682	1,198,444	521,138	1,937,909	363,593	355,108	395,675	363,593		355,108	395,675	12,744,280	415,920	169,390	251,878	11,261,113	346,707
depreciation and amortization																													1,185,611	1,154,525	818,200	803,912	794,349	843,584	741,058	449,559	290,039	855,551	276,054	395,779	403,405	270,417	454,086	448,765	449,597	454,086		448,765	449,597
acquired in-process research and development																																				10,142,786
gain on sale of fixed assets																																				45,576	-26,381			-5,316	-53,562		-39,949	-54,932	18,493	-39,949		-54,932	18,493			-33,484
net income attributable to non-controlling interests
net income attributable to arrowhead																																		-22,221,986	-15,936,053	-28,683,993	-22,575,282	-24,743,136	-11,628,919	-13,942,521	-10,628,312	-22,430,442	-6,079,010	-6,757,937	-4,614,159	-6,079,010		-6,757,937	-4,614,159	-119,021,473	-7,991,510	-5,335,233	-2,485,505	-113,355,430	-1,819,917	2,905,237	-1,437,682	-106,808,965	-371,055	-1,544,927
other comprehensive income, net of tax
comprehensive loss attributable to arrowhead																																		-14,848,825.75	-15,938,035	-28,747,958	-22,575,282	-24,813,614	-11,628,919	-13,942,521
shareholders - basic & diluted:																																					-0.41	-0.41	-0.22	-0.31	-0.28				-0.33
equity in income of unconsolidated affiliates																																							78,702	-9,597	-138,456	-9,524	-159,530	-157,612	-63,557	-159,530		-157,612	-63,557	-758,046	-34,573	-64,261	-106,527
net income attributable to noncontrolling interests																																							-2,468	40,179	57,420			182,082	166,568
impairment expense																																											1,308,047			1,308,047
income from continuing operations before income taxes																																										-22,425,232	-6,177,628	-6,939,683	-4,780,709	-6,177,628		-6,939,683	-4,780,709	-94,305,002	-8,239,738	-5,583,632	-2,686,579	-82,865,876	-1,944,672	-1,087,336	-491,883
income from continuing operations																																										-22,430,532	-6,177,628	-6,939,683	-4,780,709	-6,177,628		-6,939,683	-4,780,709	-94,305,002	-8,239,738	-5,583,632	-2,686,579	-82,865,876	-1,944,672	-1,087,336	-1,234,383	-115,217,816	-678,247	-2,230,662	-82,655,938	-2,528,617	-8,030,468	-7,787,336		-5,694,815	-5,233,774	-34,631,007	-12,477,548	-6,173,809	-3,707,170	-8,779,523	-3,974,148	-3,106,586	-3,136,953
income from discontinued operations																																												-336	-18			-336	-18	-47,546,617	677	-483	-220	-48,920,320	-68,742	-132,495	2,953	-7,187,397	-5,549	-15,767														0
net income from discontinued operations																																												-336	-18			-336	-18	-42,838,029	677	-483	-220	-48,130,945	-68,742
net (gain) loss attributable to non-controlling interests																																										90	98,618
contingent consideration - fair value adjustments
impairment of investment in unconsolidated affiliates																																																		-187,000	-1,455,775
gain on purchase of roche madison																																																					1,576,107
realized and unrealized gain in marketable securities																																																		-14,522.75			-58,091			359,920																65,252.5	124,549	133,195
gain on sale of stock in subsidiary
gain on disposal of discontinued operations																																																						789,375		3,919,213
realized and unrealized gain investments
net (income) loss attributable to noncontrolling interests																																														98,618		182,082	166,568	18,121,558	247,551	248,882	201,294	17,641,391	193,497	205,855	-206,252
weighted-average shares outstanding—basic and diluted																																														26,134,183			14,113,620				10,121,069				71,779,410		64,579,403
earnings per share - basic and diluted:
income from continuing operations attributable to arrowhead common shareholders																																																-0.41	-0.33	-0.37	-0.71	-0.5	-0.25	-0.018	-0.03		-0.02	-0.018	-0.01	-0.04
income from discontinued operations attributable to arrowhead common shareholders																																																						0.018		0.05		0.003		0.01
net income attributable to arrowhead shareholders																																																-0.41		-0.37	-0.71	-0.5	-0.25		-0.03	0.04	-0.02	-0.015	-0.01	-0.03
notes payable
earnings per share—basic and diluted:
notes payable, net of current portion																																																	-0.33
depreciation & amortization																																																		325,451.5	423,414	423,948
gain on sale of property and equipment																																																		-227,440.25	-876,277
earnings per share - basic:
weighted-average shares outstanding																																																			11,238,291	10,663,869			71,826,276	7,180,669,478,913,948
earnings per share - diluted:
salaries and payroll related costs																																																				2,017,064
earnings per share—basic:
earnings per share—diluted:
salaries																																																					1,320,693	18,889,495	354,223	787,696	1,056,437	41,268,908	914,336	1,104,103	33,739,318	889,428	3,134,826	3,896,950		3,343,701	2,911,290	13,839,676	2,800,420	2,014,740	1,726,548	1,604,726	2,036,639	1,463,539	1,366,266
amortization of intangible assets																																																					71,618
patent amortization																																																						1,600,588	60,452	60,452	78,906	1,865,372	78,906	78,906	1,478,277	100,103	89,530	102,602		103,991	103,991
loss on equity of investments - nanotope																																																						-626,886	-70,366
loss on sale of fixed assets																																																													-51,802	-78,029
realized and unrealized gain on marketable securities																																																						259,531	-498,406
gain on equity of investments - nanotope																																																								-74,827
consulting																																																									230,528	7,959,193	207,746	101,239	6,706,545	406,212	598,757	902,031		687,166	583,032	2,389,209	637,052	389,638	231,406	309,993	171,375	149,874	118,478
gain on equity of investments—nanotope																																																									48,826
gain on sale of equity of investments—ensysce
change in value of derivative liability																																																									465,270	209,157	1,552,228
gain from discontinued operations																																																									2,953							285,174
loss on equity of investments—nanotope																																																										-41,431.75	-66,489	-48,639
gain/(loss) on sale of fixed assets																																																										-129,493	13,000
gain/(loss) from discontinued operations																																																										-7,546,772	-5,549
gain/(loss) on disposal of discontinued operations																																																										359,375
less: net income attributable to noncontrolling interests																																																										15,597,848	312,741	271,502
gain/loss on disposal of discontinued operations																																																												430,000
earnings per share-basic and diluted:
weighted-average shares outstanding, basic and diluted																																																												58,649,086						38,754,239			36,422,464	34,232,149	34,181,399	31,953,806			27,987,281
revenue, note 1																																																													892,641	2,633,191	701,723	235,372		729,766	402,861
loss on equity of invesment—nanotope																																																													-44,428.5	-48,302
gain on sale of equity of investment—ensysce																																																													175,000		700,000
income before minority interests																																																													-97,943,616	-2,528,617	-8,030,528	-9,781,424		-6,839,810	-6,569,750	-40,404,040	-13,159,015	-8,108,440
minority interests																																																													15,287,678		60	1,994,088		1,144,995	1,335,976	5,773,033	681,467	1,934,631	453,253	-285,644	221,298	584,499	796,437
income from operation of discontinued—nanotechnica, inc.
loss on disposal of nanotechnica, inc.
income from operation of discontinued—aonex technologies, inc.
gain on sale of aonex technologies, inc.																																																																306,344
loss per share from continuing operations, diluted and undiluted																																																													-0.093	-0.06
loss per share, diluted and undiluted																																																													-0.093	-0.06
weighted-average shares outstanding, diluted and undiluted																																																														43,353,848	42,934,517				38,626,023
loss on equity of investment—nanotope																																																															-69,382
income from continuing operations per share, diluted and undiluted																																																															-0.19				-0.14
cost of goods sold																																																																160,742		394,817	327,206
gross profit on sales																																																																74,630		334,949	75,655	1,583,988	274,998
income from discontinued operations—nanotechnica, inc.
income from discontinued operations—aonex technologies, inc.																																																																-21,170
income from continuing operations per share, basic & diluted																																																																-0.2
income from discontinued operations per share, basic & diluted																																																																0.01
weighted-average shares outstanding, basic & diluted																																																																38,891,995
income from operation of discontinued nanotechnica, inc.
income from continuing operations per share, basic and diluted																																																																		-0.15		-0.16	-0.34	-0.18	-0.11				-0.11
cost of good sold																																																																				86,900.25	347,601
patents amortization																																																																				77,993.25	103,991	103,991
goodwill impairment & other charges
general & administrative expenses																																																																							1,176,929				1,098,095
research & development																																																																							1,349,849				1,722,393
realized & unrealized gain in marketable securities																																																																											3,266
patents - amortization																																																																								-45,330	-60,440		-60,440
income from continuing operations per share, undiluted																																																																								-0.083	-0.12	-0.1
weighted-average shares outstanding, undiluted																																																																									33,810,131	32,151,954
patents—amortization																																																																										-60,440
income from continuing operations per share, fully diluted																																																																										-0.1
weighted-average shares outstanding, fully diluted																																																																										32,151,954

We provide you with 20 years income statements for Arrowhead Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arrowhead Pharmaceuticals stock. Explore the full financial landscape of Arrowhead Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Arrowhead Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.